By Analou de Vera
The Department of Health (DOH) will deploy a total of 500 nurses to monitor the condition of those children who were administered with Dengvaxia vaccine, a health official said.
(ALVIN KASIBAN/ MANILA BULLETIN FILE PHOTO)
Health Undersecretary Rolando Enrique Domingo said that DOH Secretary Francisco Duque III has already approved the deployment of 150 nurses in Central Luzon, Calabarzon region, National Capital Region, and in Cebu.
Domingo said that they will hire the remaining 350 nurses once the Congress approves the health department's request to use the P1.16 billion refunded money from Sanofi Pasteur.
"So, yung original na 150, iyon yung nauna natin from the regular budget of the DOH doon sa deployment program natin. Yung 350, ayun yung awaiting pa natin na go signal from Congress for us to use the money," said Domingo.
The DOH announced that they already spent P22 million for the medical needs of at least 3,000 Dengvaxia vaccinees who were hospitalized.
The health department suspended the school-based immunization program last December 2017 after Sanofi Pasteur revealed that the Dengvaxia vaccine may posed potential health risk to first-time dengue patients.
(ALVIN KASIBAN/ MANILA BULLETIN FILE PHOTO)
Health Undersecretary Rolando Enrique Domingo said that DOH Secretary Francisco Duque III has already approved the deployment of 150 nurses in Central Luzon, Calabarzon region, National Capital Region, and in Cebu.
Domingo said that they will hire the remaining 350 nurses once the Congress approves the health department's request to use the P1.16 billion refunded money from Sanofi Pasteur.
"So, yung original na 150, iyon yung nauna natin from the regular budget of the DOH doon sa deployment program natin. Yung 350, ayun yung awaiting pa natin na go signal from Congress for us to use the money," said Domingo.
The DOH announced that they already spent P22 million for the medical needs of at least 3,000 Dengvaxia vaccinees who were hospitalized.
The health department suspended the school-based immunization program last December 2017 after Sanofi Pasteur revealed that the Dengvaxia vaccine may posed potential health risk to first-time dengue patients.